Hisashi Nagai
Overview
Explore the profile of Hisashi Nagai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagai H, Chen H, Karube R, Koitabashi Y, Numata O, Yamahara K
Cureus
. 2024 Sep;
16(8):e66164.
PMID: 39233947
There are no effective treatment options for patients with poor performance status and limited liver reserve, classified as Child-Pugh Grade B and C. A 61-year-old man with a prior medical...
2.
Chen H, Ishihara M, Kazahari H, Ochiai R, Tanzawa S, Honda T, et al.
Cancer Med
. 2024 Sep;
13(17):e70166.
PMID: 39225556
Background: Cancer cachexia affects more than half of all cancer patients, reducing survival rates. Evidence-based approaches are urgently needed to optimize treatment. Methods: A systematic review and network meta-analysis were...
3.
Nagai H, Chen H, Karube R, Koitabashi Y, Numata O, Yamahara K
Cureus
. 2024 Jul;
16(7):e64972.
PMID: 39035592
There is no established treatment for terminal cancer patients who no longer respond to surgery, radiotherapy, or chemotherapy, and palliative care is the standard worldwide. We performed intensity-modulated radiation therapy...
4.
Nagai H
Cureus
. 2024 Apr;
16(3):e57144.
PMID: 38559531
Among cervical cancers, small cell undifferentiated carcinoma is rare. Because of its rapid progression, the prognosis is extremely poor. During the course of cisplatin-based chemotherapy for stage Ⅳ small cell...
5.
Nagai H, Karube R
Cureus
. 2024 Mar;
16(3):e56685.
PMID: 38523872
A patient with bilateral ovarian cancer, peritoneal dissemination, and multiple liver and lung metastases was found with a sudden accumulation of ascites six months after delivery. Chemotherapy was started, but...
6.
Nagai H, Karube R
Cureus
. 2023 Dec;
15(11):e49221.
PMID: 38143707
Introduction: It is a well-known fact that anti-tumor immunity is a crucial long-term survival factor in cancer. Wilms' tumor 1 (WT1) dendritic cell vaccine therapy (WT1-DC) is an immuno-cell therapy...
7.
Nagai H, Karube R, Zhao F
Cureus
. 2023 Dec;
15(11):e48412.
PMID: 38074069
In advanced lung adenocarcinoma with metastases, the current standard of care does not in principle include aggressive cancer treatment with surgery and radiotherapy. Therefore, when chemotherapy cannot be continued, the...
8.
Nagai H, Karube R
Cureus
. 2023 Nov;
15(10):e47320.
PMID: 38022278
WT1-pulsed dendritic cell (WT1-DC) therapy was performed for end-stage squamous cell lung cancer that rapidly worsened soon after completion of carboplatin and paclitaxel. A rapid improvement in immune profile was...
9.
Hosomichi J, Kuma Y, Oishi S, Nagai H, Maeda H, Usumi-Fujita R, et al.
Am J Orthod Dentofacial Orthop
. 2017 Feb;
151(2):363-371.
PMID: 28153167
Introduction: In this study, we aimed to examine the role of intermittent hypoxia (IH) in dentofacial morphologic changes in growing rats. Methods: Seven-week-old male rats were exposed to IH at...
10.
Oishi S, Shimizu Y, Hosomichi J, Kuma Y, Maeda H, Nagai H, et al.
Front Physiol
. 2016 Oct;
7:416.
PMID: 27695422
Intermittent hypoxia (IH) recapitulates morphological changes in the maxillofacial bones in children with obstructive sleep apnea (OSA). Recently, we found that IH increased bone mineral density (BMD) in the inter-radicular...